Key Points
- CFO Kevin Tan sold 5,704 shares on Jan. 13 at an average price of $5.27 for ~$30,060, trimming his stake by 11.01% to 46,100 shares per an SEC filing.
- Solid Biosciences has near-term clinical catalysts, including an FDA Orphan Drug designation for SGT‑212 and the first participant dosed in the Phase 1b FALCON trial, with initial data planned for H2 2026.
- The stock trades around $5 (50-day $5.25, 200-day $5.61) with a market cap of about $402M, recent negative earnings (EPS -$0.48) and a consensus "Moderate Buy" analyst rating with an average target of $14.70.
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 5,704 shares of Solid Biosciences stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $5.27, for a total transaction of $30,060.08. Following the completion of the sale, the chief financial officer directly owned 46,100 shares of the company's stock, valued at approximately $242,947. The trade was a 11.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Solid Biosciences Trading Down 1.5%
SLDB opened at $5.16 on Wednesday. The company's fifty day moving average price is $5.25 and its two-hundred day moving average price is $5.61. Solid Biosciences Inc. has a 1-year low of $2.41 and a 1-year high of $7.37. The company has a market cap of $402.02 million, a price-to-earnings ratio of -2.07 and a beta of 2.69.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, equities analysts forecast that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Solid Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its holdings in Solid Biosciences by 32.2% during the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock worth $667,000 after buying an additional 43,910 shares during the last quarter. Bollard Group LLC bought a new position in shares of Solid Biosciences during the 2nd quarter valued at approximately $1,761,000. Geode Capital Management LLC increased its stake in shares of Solid Biosciences by 184.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company's stock worth $7,356,000 after purchasing an additional 979,294 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of Solid Biosciences in the 2nd quarter worth approximately $54,000. Finally, Franklin Resources Inc. lifted its stake in Solid Biosciences by 28.9% in the second quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company's stock valued at $7,788,000 after purchasing an additional 358,473 shares during the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
SLDB has been the topic of a number of recent research reports. Citigroup restated a "market outperform" rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Solid Biosciences in a research note on Wednesday, October 8th. Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the stock an "overweight" rating in a report on Tuesday, November 4th. Chardan Capital reiterated a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of Solid Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, October 19th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Solid Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $14.70.
View Our Latest Stock Analysis on SLDB
Solid Biosciences News Roundup
Here are the key news stories impacting Solid Biosciences this week:
- Positive Sentiment: SGT‑212 received FDA Orphan Drug designation for Friedreich’s ataxia — regulatory incentives (orphan, fast track, rare pediatric disease designations) can improve development pathway and potentially extend market exclusivity, supporting longer‑term value for the FA program. Article Title
- Positive Sentiment: First participant dosed in the Phase 1b FALCON trial for SGT‑212 — clinical start and the planned initial data readout in H2 2026 create a concrete near‑term catalyst; success could materially re‑rate the program. Article Title
- Positive Sentiment: 2026 outlook emphasizes neuromuscular and cardiac pipeline momentum: company reports 33 participants dosed in the Phase 1/2 INSPIRE Duchenne trial (SGT‑003) as of Jan 9, 2026 and says SGT‑003 is generally well tolerated on a steroid‑only immunomodulation regimen—this progress and expanded access to next‑gen capsid SLB101 support multiple program value drivers. Article Title
- Neutral Sentiment: Company presented at the J.P. Morgan Healthcare Conference (transcript available) — investor Q&A and corporate messaging can influence sentiment, but impact depends on new data or guidance provided in the session. Article Title
- Neutral Sentiment: Reported short‑interest data appears unreliable (showing 0 shares / NaN change); no clear signal from shorts about directional pressure based on the posted figures. (Internal market data)
- Negative Sentiment: CFO Kevin Tan sold 5,704 shares at an average $5.27 — insider selling can be interpreted negatively by the market, especially when combined with current negative earnings and uncertainty around clinical readouts. SEC filing: SEC Filing (news summary: Insider Trade Report)
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company's primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.
Solid's lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
